Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density

Abstract

Desferrioxamine (DFO) is a clinically approved, high affinity iron chelator used for the treatment of iron overload. Due to its short half-life and toxicity, DFO is administered for 8-12 h per day, 5-7 d per week. In this manuscript, the influence of molecular properties of hyperbranched polyglycerol (HPG)-DFO conjugates on their iron binding by isothermal titration calorimetry, iron removal efficiency from ferritin in presence and absence of a low molecular weight (MW) iron chelator, and protection against iron mediated oxidation of proteins is reported. The iron binding properties of HPG-DFO are slightly altered with size and DFO density of conjugates. The lower MW conjugate shows greater iron removal efficiency at room temperature, however, the efficacy of high MW conjugates increases at physiological temperature. The iron removal from ferritin by HPG-DFO conjugates increases significantly in presence of a low MW chelator, suggesting the potential of combination therapy. The molecular properties of the polymer scaffold also have influence on the prevention of iron mediated oxidation of proteins by the conjugates. The results therefore help to define the iron binding thermodynamics of HPG-DFO and their dependence on MW, and can be extended to improve the general understanding of polymeric chelator-iron interactions in situ.

Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice

“…The clinical application of iron chelators has a bright future in PD therapy; however, challenges remain in the identification of an iron chelator that simultaneously exhibits the following four qualities: natural security, low molecular weight, varying affinities for iron and good brain-targeting efficiency [9], [10]. It is therefore necessary to screen an iron chelator with all properties; thus, we turned our attention to lactoferrin (Lf).…”

Iron in Neurodegeneration – Cause or Consequence?

“…However, the numerous physiological functions of iron and defects resulting from aggressive iron depletion need to be considered. Therefore, the following features of treatment of brain iron dyshomeostasis could be taken into account: ability to pass BBB and consecutive cell membranes; chelation of excess iron with moderate affinity to avoid depletion of transferrin and iron-associated proteins; prevention of side effects due to iron removal in areas lacking iron overload (Boddaert et al, 2007; Hamilton et al, 2017; Loza-Rosas et al, 2017). Here, we will discuss potential candidates based on those selection criteria.…”

Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers

“…Binding to polymer generally decreases the rate of metal chelation and especially trans-chelation from natural iron-containing proteins, such as ferritin, compared to free chelator; however, the rate is usually sufficient even for polymers or combination with low-molecular-weight chelator can be utilized [106]. This effect can be easily explained by steric reasons (trans-chelation of iron from one macromolecule to another most plausibly requires direct contact of chelating sites, as binding constants for iron are usually very high for both native biomolecule and the polymer trans-chelator) and diffusion reasons (this is especially the case of systems where the chelator is "buried" inside the polymer).…”